Anti-diabetic drug utilization of pregnant diabetic women in us managed care

BMC Pregnancy and Childbirth

Almut G Winterstein¹  Joseph AC Delaney³  Caitlin A Knox² 

[1] Colleges of Medicine and Public Health and Health Professions, University of Florida, Gainesville, FL, USA;Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, Gainesville, FL, USA;Department of Epidemiology, University of Washington, Seattle, WA, USA

关键词: Managed care;    Pregnancy;    Drug utilization;    Pharmacoepidemiology;   

Others  :  1131764
DOI  :  10.1186/1471-2393-14-28

 received in 2013-04-05, accepted in 2013-12-23,  发布年份 2014

【 摘 要 】

Background

With the increasing prevalence of type 2 diabetes in young adulthood, treatment of diabetes in pregnancy faces new challenges. Anti-diabetic drug utilization patterns of pregnant women with pre-existing diabetes are poorly described. We aim to describe anti-diabetic (AD) agent utilization among diabetic pregnant women.

Methods

We utilized IMS LifeLink, including administrative claims data of patients in US managed care plans, to establish a retrospective cohort of women, age 18–46 years (N = 96,740) with billed procedures for a live birth, and a 12 month eligibility period before and 3 month after delivery. Diabetes mellitus was identified from ≥2 in- or outpatient claims with diagnoses (ICD-9-CM 250.XX) before pregnancy. We estimated the prevalence of AD drugs before, during and after pregnancy, and secular trends across the study period (1999–2009), using linear regression. A sensitivity analysis was conducted to identify the extent of misclassification of trimesters.

Results

Almost six percent (n = 5,581) of the live birth cohort had diabetes mellitus. Throughout the study, 48% (1999) and 78% (2009) (p < 0.0001) of diabetic women received AD drugs during pregnancy. The most common AD drugs during pregnancy were insulin, metformin, sulfonylureas, thiazolidinediones (TZD), and combination AD. The annual prevalence of insulin use increased by only 1% from 39% (1999) to 40% (2009) (p = 0.589) during pregnancy, while use of sulfonylureas and metformin increased from 2.5% and 4.2% (1999) to 17.3% and 15.3% (2009) (p < 0.0001), respectively. Insulin and sulfonylurea use steadily increased in prevalence from the 1st to 3rd trimester (16.5% and 3.3% to 33.0% and 7.5%), while metformin and TZD use decreased (11.4% and 1.6% to 3.8% and 0.2%).

Conclusions

AD use during pregnancy demonstrates the need for additional investigation regarding safety and efficacy of AD drugs on maternal outcomes.

【 授权许可】

   
2014 Knox et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Diagnosed and undiagnosed diabetes in the United States, all ages, 2010. [http://www.cdc.gov/diabetes/pubs/estimates11.htm#1 webcite]
• [2]Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS, Gregg EW: Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999–2002. Diabetes Care 2006, 29(6):1263-1268.
• [3]Holing EV, Beyer CS, Brown ZA, Connell FA: Why don't women with diabetes plan their pregnancies? Diabetes Care 1998, 21(6):889-895.
• [4]Coustan DR: Pre-conception planning. The relationship's the thing. Diabetes Care 1998, 21(6):887-888.
• [5]Janz NK, Herman WH, Becker MP, Charron-Prochownik D, Shayna VL, Lesnick TG, Jacober SJ, Fachnie JD, Kruger DF, Sanfield JA: Diabetes and pregnancy. Factors associated with seeking pre-conception care. Diabetes Care 1995, 18(2):157-165.
• [6]Kitzmiller JL, Gavin LA, Gin GD, Jovanovic-Peterson L, Main EK, Zigrang WD: Preconception care of diabetes. Glycemic control prevents congenital anomalies. JAMA 1991, 265(6):731-736.
• [7]Bell R, Glinianaia SV, Tennant PW, Bilous RW, Rankin J: Peri-conception hyperglycaemia and nephropathy are associated with risk of congenital anomaly in women with pre-existing diabetes: a population-based cohort study. Diabetologia 2012, 55(4):936-947.
• [8]Schaefer-Graf UM, Buchanan TA, Xiang A, Songster G, Montoro M, Kjos SL: Patterns of congenital anomalies and relationship to initial maternal fasting glucose levels in pregnancies complicated by type 2 and gestational diabetes. Am J Obstet Gynecol 2000, 182(2):313-320.
• [9]Miller E, Hare JW, Cloherty JP, Dunn PJ, Gleason RE, Soeldner JS, Kitzmiller JL: Elevated maternal hemoglobin A1c in early pregnancy and major congenital anomalies in infants of diabetic mothers. N Engl J Med 1981, 304(22):1331-1334.
• [10]Dunne F, Brydon P, Smith K, Gee H: Pregnancy in women with Type 2 diabetes: 12 years outcome data 1990–2002. Diabet Med 2003, 20(9):734-738.
• [11]Chen G, Khan N, Walker R, Quan H: Validating ICD coding algorithms for diabetes mellitus from administrative data. Diabetes Res Clin Pract 2010, 89(2):189-195.
• [12]Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM: Identifying persons with diabetes using Medicare claims data. Am J Med Qual 1999, 14(6):270-277.
• [13]Wei WQ, Leibson CL, Ransom JE, Kho AN, Caraballo PJ, Chai HS, Yawn BP, Pacheco JA, Chute CG: Impact of data fragmentation across healthcare centers on the accuracy of a high-throughput clinical phenotyping algorithm for specifying subjects with type 2 diabetes mellitus. J Am Med Inform Assoc 2012, 19(2):219-224.
• [14]O'Malley KJ, Cook KF, Price MD, Wildes KR, Hurdle JF, Ashton CM: Measuring diagnoses: ICD code accuracy. Health Serv Res 2005, 40(5 Pt 2):1620-1639.
• [15]Zgibor JC, Orchard TJ, Saul M, Piatt G, Ruppert K, Stewart A, Siminerio LM: Developing and validating a diabetes database in a large health system. Diabetes Res Clin Pract 2007, 75(3):313-319.
• [16]Toh S, Mitchell AA, Werler MM, Hernández-Díaz S: Sensitivity and specificity of computerized algorithms to classify gestational periods in the absence of information on date of conception. Am J Epidemiol 2008, 167(6):633-640.
• [17]Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA, Fortman KK, McPhillips H, Roblin D, Smith DH, et al.: Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf 2006, 15(8):546-554.
• [18]Hardy JR, Leaderer BP, Holford TR, Hall GC, Bracken MB: Safety of medications prescribed before and during early pregnancy in a cohort of 81,975 mothers from the UK general practice research database. Pharmacoepidemiol Drug Saf 2006, 15(8):555-564.
• [19]Margulis AV, Setoguchi S, Mittleman MA, Glynn RJ, Dormuth CR, Hernández-Díaz S: Algorithms to estimate the beginning of pregnancy in administrative databases. Pharmacoepidemiol Drug Saf 2012, 22(1):16-24.
• [20]Association AD: Standards of medical care in diabetes–2011. Diabetes Care 2011, 34(Suppl 1):S11-61.
• [21]2003 National Diabetes Fact Sheet. [http://www.cdc.gov/diabetes/pubs/general.htm#treatment webcite]
• [22]Association AD: Standards of medical care in diabetes–2009. Diabetes Care 2009, 32(Suppl 1):S13-61.
• [23]Bulletins ACoP: ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 60, march 2005. Pregestational diabetes mellitus. Obstet Gynecol 2005, 105(3):675-685.
• [24]Rowan JA, Hague WM, Gao W, Battin MR, Moore MP, Investigators MT: Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008, 358(19):2003-2015.
• [25]Group GD: Management of diabetes from preconception to the postnatal period: summary of NICE guidance. BMJ 2008, 336(7646):714-717.
• [26]Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L: Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002, 17(11):2858-2864.
• [27]Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O: A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000, 343(16):1134-1138.
• [28]Jacobson GF, Ramos GA, Ching JY, Kirby RS, Ferrara A, Field DR: Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol 2005, 193(1):118-124.
• [29]Koren G: Glyburide and fetal safety; transplacental pharmacokinetic considerations. Reprod Toxicol 2001, 15(3):227-229.
• [30]Carpenter MW, Coustan DR: Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol 1982, 144(7):768-773.
• [31]Kho AN, Hayes MG, Rasmussen-Torvik L, Pacheco JA, Thompson WK, Armstrong LL, Denny JC, Peissig PL, Miller AW, Wei WQ, et al.: Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study. J Am Med Inform Assoc 2012, 19(2):212-218.